Skip to main content
. 2020 Dec 8;11:598702. doi: 10.3389/fphar.2020.598702

TABLE 3.

Effects of roflumilast alone or combined with formoterol on the release of TNF-α, IL-6 and CC and CXC chemokines by human bronchial explants stimulated with LPS.

Cytokine (ng/100 mg) LPS (1 µg/mL)
T R (1 nM) R (100 nM) F F + R (1 nM) F + R (100 nM)
TNF-α (n = 8) 0.54 ± 0.07 0.32 ± 0.10** 0.14 ± 0.05*** 0.36 ± 0.09* 0.20 ± 0.06*** 0.09 ± 0.03***
41% 74% 33% 63% 83%
CCL2 (n = 9) 61.5 ± 11.4 45.8 ± 8.6** 35.1 ± 7.6*** 44.9 ± 8.6* 35.6 ± 7.7*** 27.9 ± 6.4***
25% 43% 27% 42% 55%
CCL3 (n = 9) 7.6 ± 0.9 4.1 ± 1.0* 1.9 ± 0.4*** 5.5 ± 0.8* 2.8 ± 0.6*** 1.5 ± 0.3***
46% 75% 27% 63% 80%
CCL4 (n = 10) 7.9 ± 1.6 4.8 ± 1.5** 2.0 ± 0.7*** 6.7 ± 1.5 3.3 ± 1.0*** 1.6 ± 0.6***
39% 74% 15% 58% 79%
CCL5 (n = 9) 0.19 ± 0.02 0.14 ± 0.03** 0.11 ± 0.01** 0.15 ± 0.03 0.11 ± 0.01** 0.09 ± 0.01***
26% 42% 21% 42% 53%
CXCLl (n = 6) 151.1 ± 23.8 116.7 ± 21.6 126.3 ± 32.2 119.6 ± 22.7 134.5 ± 42.5 105.5 ± 35.9
CXCL5 (n = 6) 16.6 ± 3.7 15.8 ± 3.7 13.7 ± 2.7 16.0 ± 4.0 15.9 ± 3.2 13.2 ± 1.9
CXCL8 (n = 11) 656.4 ± 106.7 529.6 ± 79.3* 477.8 ± 62.7** 613.8 ± 97.1 531.5 ± 80.3 434.9 ± 80.2**
20% 25% 6% 19% 34%
CXCL9 (n = 13) 4.8 ± 0.9 3.6 ± 0.8** 2.7 ± 0.6*** 4.3 ± 0.9 2.9 ± 0.6*** 2.3 ± 0.5***
25% 43% 10% 39% 48%
IL-6 (n = 9) 373.2 ± 78.3 323.8 ± 85.6 241.2 ± 44.1** 281.4 ± 52.2* 284.2 ± 69.8 208.2 ± 59.3***
35% 25% 44%

Bronchial explants were pre-treated with vehicle (T), roflumilast (R: 1 nM or 100 nM), formoterol (F: 10 nM) or a combination of formoterol and roflumilast (F + R) before being stimulated with LPS (1 µg/mL) for 24 h. Data are quoted as the mean ± SEM for the number of independent experiments indicated in brackets. *p < 0.05; **p < 0.01; ***p < 0.001 vs. LPS (T). The significant or relevant results (in italics) are also expressed as the percentage inhibition vs T (LPS alone).